The Effect of Nano-Albumin Paclitaxel on the Early Postoperative Recurrence of Primary Liver Cancer

This study aimed at investigating the clinical effect and safety of albumin binding paclitaxel (Nab-P) for the first-line treatment of advanced primary liver cancer. Clinical data of 23 patients with primary liver cancer, who were treated in the first-line tumor treatment Department in the PLA General Hospital from May 2014 to December 2015, were analyzed retrospectively. The patients were divided into an observation group and a control group, according to their treatment plan. The patients in the observation group (12) received Nab-P treatment (5 cases of Nab-P combined with tegeor, 5 cases of Nab-P combined with capecitabine, and 2 cases of Nab-P single drug), and the patients in the control group (11) received gemcitabine combined with oxaliplatin. Each treatment cycle lasted for 21 days, and the treatment effect was evaluated once every two cycles, while the adverse reactions were assessed after every cycle. The survival rates of the different groups were compared using the chi-square test or the Fisher’s exact test, the Kaplan Meier survival curve, and the log rank test. Results from all patients were used to evaluate treatment efficacy and adverse reactions. In the observation group, there were 2 cases of partial remission, 7 cases of disease stability, and 3 cases of disease progress; in the control group, there were 2 cases of partial remission, 5 cases of disease stability, and 4 cases of disease progress. There was no significant difference in disease control rate between the two groups (75% vs. 64%, χ2 = 0.350, P > 0.05). There was no significant difference in the median progression free survival time between the two groups (5.1 (2.7–6.7) months versus 4.3 (2.5–54) months, χ2 =0.647, P > 0.05). No serious side effects were observed in any of the two groups. Among the observed side effects were some PLT toxicity and increased AST (Aspartate transaminase) incidence, which showed a statistically significant difference between the two groups (χ2 = 5.490, P = 0.036 for PLT; χ2 = 6.135, P = 0.027 for AST). The new Nab-P-based drug regimen has a good effect against primary liver cancer, and the side effects are tolerable. However, the sample size used in this study was small and further clinical studies using larger samples are required to verify the results.

Download Full-text

Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.36.4.1831 ◽

2020 ◽

Vol 36 (4) ◽

Author(s):

Xuewen Wo ◽

Jinyan Han ◽

Jiajia Wang ◽

Xinmin Wang ◽

Xiaoying Liu ◽

...

Keyword(s):

Plasma Level ◽

Cerebral Infarction ◽

Antiplatelet Therapy ◽

Adverse Reactions ◽

Dual Antiplatelet Therapy ◽

Acute Cerebral Infarction ◽

Control Group ◽

Observation Group ◽

Significant Difference ◽

Better Than

Objective: To observe the clinical efficacy of sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of elderly patients with acute cerebral infarction (ACI). Methods: One hundred and twenty-two elderly patients with ACI who were admitted to the department of neurology of our hospital at May 2016-August 2018 were selected grouped into a control group and an observation group by random number table method, 61 in each group. On the basis of conventional treatment, the patients in the control group were given dual antiplatelet therapy (aspirin enteric-coated tablets + clopidogrel bisulfate tablets), while the patients in the observation group were given sequential butylphthalide therapy on the basis of the control group. The clinical effects of the two groups were compared after four weeks of treatment, and the changes of National Institutes of Health Stroke Scale (NIHSS), ADL score, plasma 3-mercaptopyruvate sulphurtransferase (3-MST) and Amyloid β42 (Aβ42) levels and the occurrence of adverse reactions during treatment were recorded. Results: The clinical efficacy of the observation group was better than that of the control group (P<0.05). There was no significant difference in NIHSS and ADL scores between the two groups before treatment (P>0.05). After treatment, the NIHSS and ADL scores of the observation group were better than those of the control group (P<0.05). There was no significant difference in plasma levels of 3-MST and AB42 between the two groups before treatment (P>0.05). The level of plasma 3-MST in the observation group was higher than that in the control group, and the level of plasma Aβ42 was lower than that in the control group (P<0.05). No serious adverse reactions occurred during the treatment period in both groups. Conclusion: Butylphthalide sequential therapy combined with dual antiplatelet therapy is effective in the treatment of elderly ACI. It can effectively improve the plasma level of 3-MST and decrease the plasma level of Aβ42, which is conducive to improving the living ability and neurological function of patients and has high safety. doi: https://doi.org/10.12669/pjms.36.4.1831 How to cite this:Wo X, Han J, Wang J, Wang X, Liu X, Wang Z. Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction. Pak J Med Sci. 2020;36(4):---------. doi: https://doi.org/10.12669/pjms.36.4.1831 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Clinical Effect of Iodine-125 Seed Implantation in Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood

Journal of Oncology ◽

10.1155/2021/6199732 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Xiaoyan Chen ◽

Fan Zhu ◽

Bin Wang ◽

Yu Zhou ◽

Hao Xiong ◽

...

Keyword(s):

Liver Cancer ◽

Tumor Markers ◽

Recurrence Rate ◽

Peripheral Blood ◽

Primary Liver Cancer ◽

Th2 Cells ◽

Control Group ◽

Observation Group ◽

Seed Implantation ◽

Iodine 125

Objective. To investigate the clinical effect of iodine-125 seed implantation combined with chemotherapy in patients with primary liver cancer and the effect on peripheral blood Th1/Th2 cells. Methods. A total of 136 patients with primary liver cancer from April 2017 to June 2018 were selected as subjects and randomly divided into the control group and observation group with 68 cases in each group. The control group was treated with chemotherapy, and the observation group was treated with iodine-125 seed implantation on the basis of the control group. After 3 months of treatment, the curative effect was investigated. Serum tumor markers, peripheral blood Th1/Th2 cells, and side effects and recurrence rate were compared between the two groups. Results. The levels of serum tumor markers in both groups at 3 months after treatment were lower than before treatment ( P < 0.05 ). Three months after treatment, the levels of tumor markers AFP, AFP-L3, and GP73 in the observation group were 14.61 ± 3.49 μg/L, 3.29 ± 0.41 ng/mL, and 51.24 ± 4.51 μg/L, respectively, which were lower than those in the control group, 32.53 ± 4.59 μg/L, 5.63 ± 0.63 ng/mL, and 71.52 ± 6.05 μg/L ( P < 0.05 ). At 3 months after treatment, the level of including interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) in Th1 cells of the observation group was higher than that of the control group ( P < 0.05 ), whereas the levels of IL-4, IL-6, and IL-10 in Th2 cells were lower than those in the control group ( P < 0.05 ). There was no statistical significance in the incidence of leukopenia, thrombocytopenia, and gastrointestinal reactions between the two groups ( P > 0.05 ). The recurrence rate of the observation group at 12, 24, and 36 months after treatment was lower than that of the control group ( P < 0.05 ). Conclusion. Iodine-125 seed implantation combined with chemotherapy in patients with primary liver cancer can reduce the level of serum tumor markers, improve the level of peripheral blood Th1/Th2 cells, and reduce the recurrence rate of patients without increasing the incidence of side effects, which is worthy of promoting the application of iodine-125 seed implantation.

Download Full-text

Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

10.21203/rs.3.rs-306501/v1 ◽

2021 ◽

Author(s):

Jing Wu ◽

Hao Jiang ◽

Liting Chen ◽

Bingqi Yu ◽

Zhibing Wu

Keyword(s):

Qualitative Data ◽

Adverse Reactions ◽

Clinical Effect ◽

Objective Response ◽

Malignant Ascites ◽

Control Group ◽

Observation Group ◽

Improvement Rate ◽

Significant Difference

Abstract Objective：The purpose of this study is to retrospectively observe the clinical efficacy and adverse reactions of docetaxel hyperthermic intraperitoneal chemotherapy (HIPEC) combined with endostar in treatment of malignant ascites. Methods：56 cases of malignant ascites admitted to Zhejiang Hospital from July 2019 and October 2020 had received no less than second-line chemotherapy. The observation group (n = 29) was treated with endostar 60mg d1,4,7 Q3W intraperitoneal injection combined with docetaxel 60mg/m2 d4 HIPEC Q3W for 2 cycles. The control group (n = 27) was just treated with docetaxel 60mg/m2 d1 HIPEC Q3W for 2 cycles. The general clinical data and qualitative data of the treatment results were processed by SPSS26.0 using χ2 test, and quantitative data were processed by t test. When P < 0.05, statistical data can be considered statistically significant.Results：There were significant differences between the observation group and the control group in objective response rate (ORR) (65.5% vs 37.0%，P=0.033)，in the improvement rate of KPS (48.3% vs 22.2%, P=0.042)，also in the median control time (57dvs 45d，P=0.027). The incidence of III to IV adverse reactions was low, and no treatment-related death was observed. There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion：Endostar combined with docetaxel HIPEC has good clinical effect on malignant ascites and can improve patients’ quality of life, and the adverse reactions can be tolerated.

Download Full-text

Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Malignant Ascites

10.21203/rs.2.23958/v2 ◽

2020 ◽

Author(s):

Jie Jiao ◽

Chengzhen Li ◽

Guanying Yu ◽

Lei Zhang ◽

Xiaoyan Shi ◽

...

Keyword(s):

Intraperitoneal Chemotherapy ◽

Adverse Reactions ◽

Total Effective Rate ◽

Malignant Ascites ◽

Effective Rate ◽

Control Group ◽

Observation Group ◽

Short Term ◽

Significant Difference ◽

The Difference

Abstract Objective: The purpose of this study is to compare the difference of clinical efficacy between conventional intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC.Design: A retrospective analysis was conducted on 80 patients with malignant ascites admitted to our hospital from June 2017 to June 2019. The general clinical data and qualitative data of the treatment results of 80 patients with malignant ascites were processed by SPSS19.0 using χ2 test and quantitative data were processed by t test. P <0.05, statistical data can be considered statistically significant.Results: 1. There was no significant change in vital signs and temperature in the observation group during the treatment, and the difference was not statistically significant 2. The short-term total effective rate of patients in the observation group was 91.11%, and the short-term total effective rate of the patients in the control group was 40%.3. There was no significant difference in the incidence of adverse reactions between the two groups of patients.Conclusion: Intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy can significantly control malignant ascites, and has small adverse reactions, which is worthy of clinical promotion and application.

Download Full-text

Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.36.7.1964 ◽

2020 ◽

Vol 36 (7) ◽

Author(s):

Li Kong ◽

Kai Zuo ◽

Long Ma

Keyword(s):

Bone Mineral Density ◽

Zoledronic Acid ◽

Bone Mineral ◽

Adverse Reactions ◽

Clinical Effect ◽

Control Group ◽

Observation Group ◽

Mineral Density ◽

Senile Osteoporosis ◽

Significant Difference

Objective: To investigate the clinical efficacy of zoledronic acid in the treatment of senile osteoporosis. Methods: One hundred and six cases of senile osteoporosis who visited to our hospital from August 2017 to December 2018 for treatment were selected and randomly divided into a control group and an observation group. The control group was treated with conventional therapy, while the observation group was treated with zoledronic acid in addition to the treatment of the control group. Bone mineral density, pain degree, therapeutic effect and adverse reactions of the two groups were compared. Results: The total effective rate of the observation group was 96.67%, higher than 80.00% of the control group (P<0.05); the bone mineral density of lumbar vertebrae, femoral neck and Ward’ area in the two groups increased after 6 months of treatment, and the bone mineral density of the observation group increased more than that of the control group (P<0.05); the pain degree of the observation group was lower than that of the control group after 6 months of treatment, and the difference was significant (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P>0.05). Conclusion: Zoledronic acid is helpful to alleviate clinical symptoms, reduce the degree of bone pain, and promote the increase of bone mass, and has high safety in the treatment of senile osteoporosis, which is worth promotion. doi: https://doi.org/10.12669/pjms.36.7.1964 How to cite this:Kong L, Zuo K, Ma L. Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis. Pak J Med Sci. 2020;36(7):1703-1707. doi: https://doi.org/10.12669/pjms.36.7.1964 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Effect of Metoprolol on Cardiac Function and Prognosis in Patients with Dilated Cardiomyopathy

Journal of Clinical and Nursing Research ◽

10.26689/jcnr.v5i2.1929 ◽

2021 ◽

Vol 5 (2) ◽

Author(s):

Huailing Su ◽

Bin Li ◽

Zhisheng Jia

Keyword(s):

Cardiac Function ◽

Dilated Cardiomyopathy ◽

Adverse Reactions ◽

Left Ventricular ◽

Left Ventricular Ejection ◽

Control Group ◽

Observation Group ◽

Significant Difference ◽

Conventional Methods ◽

The Difference

Objective: To investigate the effect of metoprolol on cardiac function and prognosis in patients with dilated cardiomyopathy. Methods: 100 patients with dilated cardiomyopathy treated in our hospital from January 2018 to December 2019 were randomly divided into control group (n = 50) and observation group (n = 50). The control group was treated with conventional methods, and the observation group was treated with conventional methods and metoprolol for 6 months. The cardiac function [left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac output (CO)] and prognosis [Glasgow Outcome Scale (GOS) score] of the two groups before and at the end of 6 months of intervention were compared, and the incidence of adverse reactions of the two groups were compared. Results: After 6 months of treatment, the levels of LVEF, SV and CO in the two groups were higher than before treatment, and the comparison level between the observation group and the control group was higher, the difference was statistically significant (P < 0.05);After 6 months of treatment, the GOS score of the observation group was higher than that of the control group, and the difference was statistically significant (P < 0.05);There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Metoprolol can improve the cardiac function and prognosis of patients with dilated cardiomyopathy, without increasing the incidence of adverse reactions.

Download Full-text

The Effect of Combination Use of Hemodialysis and Hemoperfusion on Microinflammation in Elderly Patients with Maintenance Hemodialysis

Blood Purification ◽

10.1159/000518857 ◽

2022 ◽

pp. 1-8

Author(s):

Jun Li ◽

Hui Li ◽

Wenjiao Deng ◽

Lixin Meng ◽

Wenya Gong ◽

...

Keyword(s):

Quality Of Life ◽

Elderly Patients ◽

Adverse Reactions ◽

Statistical Significance ◽

Continuous Treatment ◽

Maintenance Hemodialysis ◽

Control Group ◽

Observation Group ◽

Significant Difference

Background: Patients with maintenance hemodialysis (MHD) generally have a microinflammatory state. The aim of this study was to investigate the effects of hemodialysis (HD) combined with hemoperfusion (HP) on microinflammatory state in elderly patients with MHD. Methods: One hundred and fifty elderly patients with MHD were randomly divided into the control group and the observation group. The control group received simple HD treatment, and the observation group received combined HD + HP treatment on the basis of the control group. After 6 months of continuous treatment, the patients were evaluated to compare the quality of life, inflammation, adverse reactions, and nutritional indicators in the 2 groups before and after treatment. Results: There was no significant difference in the quality of life between the 2 groups before treatment. After treatment, the scores of psychological aspects, physiological aspects, social aspects, environmental aspects, and independent ability in the observation group were higher than those in the control group, with statistical significance (p < 0.05). There was no statistical significance in the level of inflammation between 2 groups before treatment. After treatment, the levels of hs-CRP, Hcy, IL-6, and TNF-α in the observation group were significantly lower than those in the control group, with statistical significance (p < 0.05). The incidence of dry mouth, skin reaction, neuritis, and subcutaneous tissue fibrosis in the observation group was lower than that in the control group, with statistical significance (p < 0.05). There was no statistical significance in nutritional level indexes between 2 groups before treatment (p1 > 0.05). After treatment, the levels of hemoglobin, total protein, albumin, and transferrin in the observation group were significantly higher than those in the control group, with statistical significance (p < 0.05). Conclusion: The clinical effect of HD combined with HP in elderly MHD patients is significant, which can effectively reduce the incidence of adverse reactions and inflammation in the patients and improve the quality of life and nutritional indicators of the patients.

Download Full-text

Long Term and Low Dose Mifepristone in The Treatment of Uterine Leiomyoma

Tobacco Regulatory Science ◽

10.18001/trs.7.5.91 ◽

2021 ◽

Vol 7 (5) ◽

pp. 1681-1685

Author(s):

Panpan Liu ◽

Meifang Dou ◽

Li’an Yi ◽

Kemei Li ◽

Fenghua Yan

Keyword(s):

Uterine Leiomyoma ◽

Adverse Reactions ◽

Low Dose ◽

Hot Flashes ◽

Control Group ◽

Observation Group ◽

Conventional Dose ◽

Long Term Effect ◽

Significant Difference

To explore the long-term effect of low-dose mifepristone in the treatment of uterine leiomyoma. Methods: 90 cases of hysteromyoma treated in our hospital from December 2018 to May 2019 were randomly divided into control group and observation group, 45 cases in each group. The control group was treated with conventional dose (25mg / D) of mifepristone, and the observation group with low dose (12.5mg / D) of mifepristone. The uterine volume, uterine fibroid volume, hormone level, therapeutic effect and adverse reactions were compared between the two groups. Results: After treatment, the volume of uterus and hysteromyoma in the two groups decreased significantly, but there was no significant difference between the observation group and the control group (P > 0.05); the level of E2, P, FSH in the two groups decreased, but there was no significant difference between the observation group and the control group (P > 0.05); the treatment effect of the observation group and the control group was no significant difference (P > 0.05); the adverse reactions of nausea, anorexia, hot flashes and fatigue in the observation group The birth rate was significantly lower than that of the control group (P < 0.05). Conclusion: Low dose mifepristone can also effectively reduce the level of estrogen and progesterone in patients with uterine leiomyoma, reduce the volume of leiomyoma, reduce the incidence of adverse reactions, with high safety, which is worthy of clinical application.

Download Full-text

Effect of Radiofrequency Ablation with Interventional Therapy of Hepatic Artery on the Recurrence of Primary Liver Cancer and the Analysis of Influencing Factors

Journal of Oncology ◽

10.1155/2021/3392433 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Sishuo Zhang ◽

Ge Zhao ◽

Honglin Dong

Keyword(s):

Radiofrequency Ablation ◽

Treatment Group ◽

Liver Cancer ◽

Hepatic Artery ◽

Primary Liver Cancer ◽

Combined Treatment ◽

Interventional Therapy ◽

Control Group ◽

Tumor Diameter ◽

Significant Difference

Background. The probability of liver cancer recurring in patients after surgery is a serious threat to liver cancer patients. Radiofrequency ablation is widely employed in liver cancer cases. We explored the therapeutic effects and influencing factors of radiofrequency ablation combined with hepatic artery intervention in patients with recurrence of primary liver cancer surgery. Methods. 90 patients with primary liver cancer postoperative recurrence admitted to our hospital from January 2014 to February 2017 were selected as the research objects. The patients were randomly divided into the control group (n = 45) and combined treatment group (n = 45). The combined treatment group received radiofrequency ablation combined with hepatic artery interventional therapy, and the control group received hepatic artery interventional therapy. The short-term efficacy, AFP levels before and after treatment, and long-term survival results of the two groups were compared. Single-factor and multifactor analyses of the clinical information of the combined treatment group were carried out to find out the factors affecting the therapeutic effect of radiofrequency ablation combined with hepatic artery intervention on patients with recurrence of primary liver cancer. Results. The total effective rate of short-term curative effect of the combined treatment group was higher than the control group, and there was a statistically significant difference existing ( P < 0.05). After treatment, two groups of patients’ AFP levels were greatly lower than before treatment, the AFP levels of the combined treatment group were significantly lower than the control group, and there was a statistically significant difference ( P < 0.05). The survival rates of patients in the combined treatment group at the sixth month, the first year, and the second year after treatment were significantly higher than those of the control group, and there was a statistically significant difference ( P < 0.05). The univariate results showed that, in the combined treatment group, there were statistically significant differences between the effective group and the ineffective group in tumor diameter, intact capsule, liver cirrhosis, intrahepatic spread, and tumor adjacent to large blood vessels ( P < 0.05). The outcomes of multivariate analysis indicated that tumor diameter ≥ 3 cm, incomplete capsule, intrahepatic spread, and tumor adjacent to large blood vessels were risk factors for ineffective recurrence of patients with primary liver cancer after radiofrequency ablation combined with hepatic artery intervention ( P < 0.05). Discussion. Tumor diameter ≥ 3 cm, incomplete capsule, intrahepatic spread, and tumor adjacent to large blood vessels are risk factors for the ineffectiveness of radiofrequency ablation combined with hepatic artery interventional therapy for patients with recurrence of primary liver cancer. It is necessary to increase the range of radiofrequency treatment, increase the temperature of the radiofrequency needle, and strengthen postoperative follow-up interventions based on the specific conditions of the patient's tumor.

Download Full-text

The Clinical Effect of Moxifen Tablets Combined with Medroxyprogesterone Acetate Injection on Patients with Endometriosis

Tobacco Regulatory Science ◽

10.18001/trs.7.5.1.105 ◽

2021 ◽

Vol 7 (5) ◽

pp. 3315-3319

Author(s):

Xiaopeng Zhang ◽

Lin Cong

Keyword(s):

Medroxyprogesterone Acetate ◽

Adverse Reactions ◽

Clinical Effect ◽

Sex Hormone ◽

Control Group ◽

Therapeutic Effects ◽

Observation Group ◽

Significant Difference ◽

Treatment Safety ◽

Significant Therapeutic Effect

Objective: To explore the clinical effect of moxifen tablets combined with medroxyprogesterone acetate injection on patients with endometriosis. Methods: 90 patients with endometriosis from August 2018 to March 2019 were randomly divided into control group and observation group, with 45 cases in each group. The control group was treated with moxifene tablets and the observation group with medroxyprogesterone acetate. The changes of serum sex hormone, P, CA125 levels, adverse reactions and therapeutic effects were compared between the two groups. Result: Before treatment, there was no significant difference in serum sex hormone and P, CA125 levels between the two groups (P > 0.05); after treatment, the indexes of the two groups were reduced, and the LH, E2, FSH, CA125 and P water in the observation group were lower than those in the control group (P < 0.05); the curative effect of the observation group was significantly better than that in the control group (P < 0.05); the incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05). Conclusion: Moxifene combined with medroxyprogesterone acetate has a significant therapeutic effect on endometriosis. It can significantly reduce the level of serum sex hormone. The incidence of adverse reactions is low and the treatment safety is high. It is worth popularizing.

Download Full-text